Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

West-Ward Parent Hikma Acquires Egypt’s Alkan Pharma

This article was originally published in The Pink Sheet Daily

Executive Summary

Multinational Hikma will strengthen its presence in the Middle East/North Africa market with $60.5 million purchase.

You may also be interested in...



Hikma Looks To Be Partner Of Choice In MENA Region Via Acquisition Of Promopharm

Jordanian drug maker Hikma Pharmaceuticals PLC acquired 63.9% of Moroccan branded generics firm Promopharm SA Oct. 3 in a cash deal worth $111.2 million. The acquisition gives Hikma access to the fourth largest pharmaceutical market in the Middle East and North Africa, additional manufacturing capacity and capability, and a perhaps stronger claim to its goal of being a partner of choice for multinationals across the MENA region

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel